Global Incidence, Prevalence, and Mortality of Type 1 Diabetes in 2021 With Projection to 2040: A Modelling Study
This is illustrated below
SUSTAIN-6 (semaglutide), LEADER (liraglutide), and REWIND (dulaglutide) all found significantly lower odds of new or worsening nephropathy with GLP1RA compared to placebo (54,55,58) (Table 3)
Brighten, Hydrate & Even Skin Tone with APLB Body Lotion
It should be noted that the musculoskeletal evidence base remains preclinical, a 2025 scoping review by McGuire and colleagues in Current Reviews in Musculoskeletal Medicine found no adequately powered randomised controlled trials
Because higher oxidative stress and inflammation status are early events in the evolution of hyperlipidemia [32, 33], we suggest that an antioxidant supply (such as LC) may help prevent or delay the development of CAD [26, 27]